
## Giuseppe Camporese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2817004/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serial 2-Point Ultrasonography Plus D-Dimer vs Whole-Leg Color-Coded Doppler Ultrasonography for Diagnosing Suspected Symptomatic Deep Vein Thrombosis. JAMA - Journal of the American Medical Association, 2008, 300, 1653.	7.4	246
2	A Randomized Study on 1-Week Versus 4-Week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer. Annals of Surgery, 2014, 259, 665-669.	4.2	162
3	Simplification of the Diagnostic Management of Suspected Deep Vein Thrombosis. Archives of Internal Medicine, 2002, 162, 907.	3.8	152
4	Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability,d-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis. Annals of Internal Medicine, 2014, 160, 451.	3.9	62
5	COVIDâ€19 and Venous Thromboembolism in Intensive Care or Medical Ward. Clinical and Translational Science, 2020, 13, 1108-1114.	3.1	46
6	Diagnosis of deep-vein thrombosis. Thrombosis Research, 2018, 163, 201-206.	1.7	36
7	Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. Lancet Haematology,the, 2015, 2, e474-e480.	4.6	35
8	Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. Thrombosis Research, 2017, 153, 97-100.	1.7	31
9	Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study. Journal of the American Heart Association, 2020, 9, e018917.	3.7	31
10	Heparin and SARS-CoV-2: Multiple Pathophysiological Links. Viruses, 2021, 13, 2486.	3.3	10
11	An association between residual vein thrombosis and subclinical atherosclerosis: Cross-sectional study. Thrombosis Research, 2017, 157, 16-19.	1.7	9
12	The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. Viruses, 2021, 13, 1720.	3.3	9
13	Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency. Medicina (Lithuania), 2021, 57, 997.	2.0	9
14	Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY. European Journal of Internal Medicine, 2020, 72, 53-59.	2.2	8
15	Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation. Advances in Therapy, 2021, 38, 2891-2907.	2.9	7
16	Risk Factors of Venous Thromboembolism in Noncritically III Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation. Viruses, 2022, 14, 737.	3.3	7
17	Clinical Differences between COVID-19 and a COVID-Like Syndrome. Journal of Clinical Medicine, 2021, 10, 2519.	2.4	6
18	Machine Learning to Calculate Heparin Dose in COVID-19 Patients with Active Cancer. Journal of Clinical Medicine, 2022, 11, 219.	2.4	6

#	Article	IF	CITATIONS
19	Edoxaban for the Longâ€Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?. Clinical and Translational Science, 2021, 14, 335-342.	3.1	0
20	Special Issue "COVID-19 and Thrombosis― Viruses, 2022, 14, 1425.	3.3	0